Home / Evidence ledger / CJC-1295
29 amino acids · GHRH analogue, with or without DAC
Not approvedThe most commonly misrepresented regulatory status in this market. CJC-1295 came off the restricted list in April 2026 and a great deal of marketing has treated that as clearance. It was not. It was not among the seven compounds the advisory panel reviewed in July, and it is on no current pathway to listing.
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
Schematic structure, not to scale. Beads represent amino acid residues along the backbone.
In theory, CJC-1295 is designed to raise your own growth hormone rather than replace it, binding the GHRH receptor to prompt pituitary release, on the logic that the body's own feedback limits stay intact. The DAC modification extends its half-life from minutes to days by binding it to albumin, which is genuinely clever pharmacology used in approved medicines. Early studies did confirm it raises GH and IGF-1. What was never shown is what that produces clinically, or over years.
The detail, if you want it
A synthetic analogue of growth hormone-releasing hormone. It exists in two forms that behave very differently. With DAC, a drug affinity complex that binds it to serum albumin, the half-life extends to roughly six to eight days, producing sustained elevation. Without DAC, often sold as modified GRF 1-29, it clears within hours and produces a shorter pulse.
It binds the GHRH receptor on the pituitary, prompting release of the body's own growth hormone rather than supplying growth hormone directly. In principle this preserves more of the natural pulsatile pattern. The long-acting DAC form arguably undermines that rationale, since continuous stimulation is not how endogenous GHRH signalling works.
That is the question a consultation answers. A licensed physician reviews your situation and tells you what the evidence supports. Including when the honest answer is no.
See consultationsAlso on the ledger